Skip to main content

Table 4 Visual acuity and central retinal thickness outcome by response to ranibizumab among nAMD subjects

From: Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects

  

Responder (n = 54)

Non-responder (n = 91)

P b

Age

 

68.33 ± 6.47

69.56 ± 8.07

0.343

Smoking

 

15 (27.8)

35 (38.5)

0.191

Mean BCVA (logMAR)a

Baseline

0.66 ± 0.27

0.51 ± 0.24

0.001*

3 months

0.57 ± 0.29

0.61 ± 0.24

0.304

6 months

0.43 ± 0.24

0.67 ± 0.28

< 0.001*

Mean CRT (μM)a

Baseline

480.3 ± 153.78

326.9 ± 87.12

< 0.001c*

3 months

348.0 ± 114.79

355.8 ± 124.27

0.642

6 months

321.5 ± 98.73

390.8 ± 145.79

0.001*

Changes in BCVA (logMAR)a

3 months

− 0.09 ± 0.20

0.10 ± 0.19

< 0.001*

6 months

− 0.23 ± 0.22

0.16 ± 0.23

< 0.001*

Changes in CRT (μM)a

3 months

− 132.3 ± 133.05

28.92 ± 83.39

< 0.001c*

6 months

− 158.9 ± 132.02

63.96 ± 119.60

< 0.001c*

  1. Data are presented as percentages in parentheses
  2. CRT central retinal thickness, BCVA best-corrected visual acuity
  3. *Significant P value, P < 0.05
  4. aData presented as mean ± standard deviation (SD)
  5. bMann-Whitney U test
  6. CStudent’s t test
Back to article page

Human Genomics

ISSN: 1479-7364